Ladenburg raised the firm’s price target on TG Therapeutics to $39 from $37.50 and keeps a Buy rating on the shares. The firm continues to be impressed with the launch of BRIUMVI and estimates 2024 revenues of $248.2M, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TGTX:
- Biotech Alert: Searches spiking for these stocks today
- TG Therapeutics price target raised to $45 from $41 at H.C. Wainwright
- Unusually active option classes on open January 10th
- TG Therapeutics (NASDAQ:TGTX) Surges after Preliminary Q4 and FY23 Results
- TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
